TG-1701 is a novel covalent BTK inhibitor
TG-1701 is a novel oral, once daily, covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor.
B-cell receptor (BCR) signaling is crucial for normal B-cell development and supports the survival and growth of malignant B-cells in patients with B-cell leukemias or lymphomas. Targeting BTK, an essential element of BCR signaling pathway which regulates the survival, activation, proliferation, and differentiation of B lymphocytes, has shown remarkable efficacy with an acceptable safety profile in B-cell malignancies.
A Phase 1 study evaluating TG-1701 as a single agent and in combination with ublituximab and umbralisib in patients with CLL and NHL is ongoing. Phase 2 and 3 trials are planned.
Please click here to view currently available clinical trials for TG-1701.
Please click here to view our Publications Page.